Form 4 Filing for Kazia Therapeutics Ltd.

This filing details a Form 4 filed by Sudha Rao, Chief Scientific Officer of Kazia Therapeutics Ltd. on June 23, 2026. The filing reports the grant of 250,000 employee stock options for ADSs, with an exercise price of $18.48 per ADS. These options vest over a period, with one-third vesting on April 13, 2026, and the remainder in equal yearly installments. The options expire on June 19, 2029. The transaction is reported as acquired (Code A) with 250,000 shares granted. Post-transaction, the reporting person holds 250,000 shares.